Welcome to our dedicated page for Prime Medicine news (Ticker: PRME), a resource for investors and traders seeking the latest updates and insights on Prime Medicine stock.
Prime Medicine Inc. (PRME) is pioneering next-generation genetic therapies through its Prime Editing platform, developing potential cures for previously untreatable diseases. This news hub provides investors and industry observers with essential updates on clinical advancements, strategic collaborations, and regulatory developments.
Access real-time updates on PRME's progress across therapeutic areas including hematology, immunology, and neuromuscular disorders. Our curated collection features official press releases, earnings reports, and analysis of key milestones in gene editing innovation.
Stay informed about PRME developments including clinical trial phases, technology partnerships, and scientific publications. All content is verified for accuracy and presented in chronological order for efficient research tracking.
Bookmark this page for streamlined access to Prime Medicine's latest corporate announcements and research breakthroughs. For comprehensive investment analysis, combine these updates with SEC filings and market performance metrics available through Stock Titan's research tools.
Prime Medicine (Nasdaq: PRME) appointed Matthew Hawryluk, Ph.D., M.B.A. as Chief Business Officer effective Nov 3, 2025. Dr. Hawryluk will lead corporate and business development, corporate strategy, and alliance management to expand Prime Editing through strategic partnerships.
He brings nearly two decades of BD and corporate leadership, including a prior role as CBO at AIRNA where he helped secure an oversubscribed $155 million Series B, and earlier transactions totaling $2.5 billion in potential value at Gritstone bio. The release also notes Prime’s earlier 2025 clinical data showing initial human safety and efficacy for Prime Editing.
Prime Medicine (Nasdaq: PRME) will host a virtual KOL event on Nov 12, 2025 at 8:00am ET to present its liver disease franchise and Wilson’s Disease strategy. The company said it remains on track to file an IND/CTA for PM577 in the first half of 2026, with initial clinical data expected in 2027. Presenters include company management and Dr. Michael Schilsky, covering Prime Editing platform modularity, the unmet need in Wilson’s Disease, and development plans. The live webcast and presentation materials will be available on Prime Medicine’s investor relations site, with an archived replay after the event.
Prime Medicine (Nasdaq: PRME) announced management will participate in two investor conferences in October 2025. A fireside chat at the H.C. Wainwright Genetic Medicines Virtual Conference will be available on demand beginning October 14, 2025, with virtual 1x1 meetings on October 15, 2025. Allan Reine, M.D., will join a panel, “Genome Editing: Next Wave Technologies,” and host 1x1 meetings at Chardan’s 9th Annual Genetic Medicines Conference on October 21, 2025 at 8:45 a.m. ET in New York.
Live audio webcasts and replays will be available under Events & Presentations on the company website, with replays accessible for 90 days after each event.
Prime Medicine (Nasdaq: PRME), a biotechnology company focused on curative genetic therapies, has announced its participation in two upcoming investor conferences in September 2025:
The company will present at Citi's 2025 Biopharma Back to School Conference on September 2 at 4:45 p.m. ET in Boston, and at the Morgan Stanley 23rd Annual Global Healthcare Conference on September 8 at 1:05 p.m. ET in New York. Live webcasts will be available on Prime Medicine's website, with replays accessible for 90 days after each event.
Prime Medicine (NASDAQ: PRME) reported Q2 2025 financial results and significant business updates. The company announced positive clinical data from two patients in their Phase 1/2 CGD trial, demonstrating the first clinical proof-of-concept for Prime Editing technology. Prime Medicine completed a follow-on offering raising $144.2 million and secured up to $24 million in additional funding from the Cystic Fibrosis Foundation.
The company reported a Q2 2025 net loss of $52.6 million, with R&D expenses of $41.4 million and G&A expenses of $13.1 million. Under new CEO Allan Reine's leadership, Prime Medicine is focusing on advancing its liver franchise programs (Wilson's Disease and Alpha-1 Antitrypsin Deficiency) and partnership-funded initiatives. The company's pro-forma cash position of $259.6 million is expected to fund operations into 2027.
Prime Medicine (Nasdaq: PRME) has successfully completed its public offering of 43.7 million shares of common stock at $3.30 per share, including the full exercise of the underwriters' option for 5.7 million additional shares. The biotechnology company, focused on developing curative genetic therapies, raised approximately $144.2 million in gross proceeds before deducting expenses.
The offering included a notable sale of 1,818,181 shares to the Cystic Fibrosis Foundation, for which underwriters received no commissions. TD Cowen and BMO Capital Markets served as joint book-running managers for the offering, which was conducted under Prime Medicine's previously filed shelf registration statement.
Prime Medicine (Nasdaq: PRME) has announced the pricing of a public offering of 38,000,000 shares of common stock at $3.30 per share. The biotechnology company expects to raise approximately $125.4 million in gross proceeds before deducting expenses.
The offering includes a notable arrangement with the Cystic Fibrosis Foundation, which will purchase 1,818,181 shares without underwriter commissions. Additionally, underwriters have a 30-day option to purchase up to 5,700,000 additional shares. The offering is expected to close around August 1, 2025, with TD Cowen and BMO Capital Markets serving as joint book-running managers.
Prime Medicine (Nasdaq: PRME), a biotechnology company focused on curative genetic therapies, has announced a proposed public offering of common stock. The company will grant underwriters a 30-day option to purchase an additional 15% of the offered shares.
The offering will be managed by TD Cowen and BMO Capital Markets as joint book-running managers. The shares will be offered through a previously filed shelf registration statement that became effective on November 13, 2023. The final terms of the offering will be disclosed in a final prospectus supplement to be filed with the SEC.
Prime Medicine (Nasdaq: PRME) has secured up to $24 million in additional funding from the Cystic Fibrosis Foundation to accelerate the development of Prime Editors for treating cystic fibrosis (CF). The funding includes a $6 million equity investment and will be provided in two tranches, subject to certain conditions and milestones.
The company's Prime Editing technology aims to permanently correct CF-related lung disease through multiple hotspot Prime Editors that could potentially benefit over 93% of CF patients. Initially, Prime Medicine will focus on targeting the G542X mutation, one of the most common CF-causing nonsense mutations currently lacking available therapies.
Prime Medicine (NASDAQ: PRME), a biotechnology company focused on developing one-time curative genetic therapies, has announced its participation in two major upcoming investor conferences. The company will present at the Jefferies Global Healthcare Conference on June 5, 2025, at 10:30 a.m. ET in New York, and the Goldman Sachs 46th Annual Global Healthcare Conference on June 9, 2025, at 2:40 p.m. ET in Miami Beach. Both presentations will be available via live audio webcasts on the company's website, with replays accessible for 90 days following each event.
FAQ
What is the current stock price of Prime Medicine (PRME)?
What is the market cap of Prime Medicine (PRME)?
